Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546986 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02546986 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 100 participants.
The verdict
NCT02546986, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG CC-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-10-09 |
| Est. Completion | 2025-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02546986
The ClinicalTrials.gov registry entry for NCT02546986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02546986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02546986 about?
NCT02546986 is a clinical study titled "Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer". The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT02546986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2015-10-09. Estimated completion is 2025-07-07.
What interventions are being tested in trial NCT02546986?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), CC-486 (DRUG).
Who is sponsoring clinical trial NCT02546986?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.